Acrivon Therapeutics, Inc.
ACRVDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Aug 12, 2026
9dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
ACRV Earnings Report
EPS Est: $-0.49 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ACR-368 | Phase 2 | Endometrial Adenocarcinoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Acrivon Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Acrivon Therapeutics, Inc.'s (ACRV) pipeline across Phase 2. Its lead program is ACR-368 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Acrivon Therapeutics, Inc.'s next FDA catalyst?→
Acrivon Therapeutics, Inc.'s (ACRV) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ACRV biotech catalysts?→
Add ACRV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Acrivon Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.